{'fraction_non_alphanumeric': 0.02358974358974359, 'fraction_numerical': 0.019487179487179488, 'mean_word_length': 5.0246913580246915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetic characteristics of the new veterinary antibiotic turimycin.

A macrolide antibiotic turimycin, is a fermentation product of Streptomyces hygroscopicus. It is active in vitro against a range of mycoplasma species and gram-positive bacteria. The antimicrobial activity of the agent was determined in serum, urine, feces and extracts of different organs. In rats, dogs and pigs the serum half life of turimycin ranged from 30 to 120 min. The absorption rate from the intestine was about 30%. After a single iv injection of turimycin into rats, the original substance and its metabolites were excreted preferably by the bile. After oral administration of turimycin to pigs (250 mg/kg daily for 14 days) and to flow (650 mg/kg daily for 10 days) antimicrobial activity was detected in fatty tissue and bile up to the 14th posttreatment day. The pharmacokinetic properties of turimycin are similar to those of corresponding macrolide antibiotics, including tylosin.